OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform
FIND, the global alliance for diagnostics, together with German KfW bank co-funds development of Unyvero A30 RQ platform for low...
Staff
BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
- The first and only treatment in Europe to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare,...
Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer
CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for...
Luc Debruyne Appointed as Observer to the Board of Directors of Bavarian Nordic
COPENHAGEN, Denmark, September 20, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the board of directors has appointed...
Skye Bioscience Completes Drug Production for Phase 1 Clinical Study
San Diego, California, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical...
Renalytix Announces Change to Board of Directors
LONDON and SALT LAKE CITY, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that Ann...
GNT Pharma Provides Update on Two Phase III Studies of Nelonemdaz for Acute Ischemic Stroke Patients Treated with tPA (ENIS-3) or Endovascular Thrombectomy (RODIN)
Promising efficacy and safety profiles were observed in prior Phase II studies in acute ischemic stroke patients treated with recanalization...
Shockwave Medical Initiates All-Female Coronary IVL Study
EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions Study Seeks to Confirm Benefits of Shockwave’s Coronary IVL...
AXIM® Biotechnologies Signs Exclusive Global Commercialization Agreement With Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions
Under the Agreement the Company will Sell and Distribute Globally AXIM’s Readers and Three Novel Proprietary Tests Designed for Diagnosis...
BTL’s Innovative New EMFACE™ Device Comes to Dr. Ellen Turner’s Dermatology Office in Dallas
Dr. Ellen Turner Leads Texas by Offering Facial Rejuvenation Treatments with the Revolutionary EMFACE™ Device, Launching Nationwide on Sept. 19DALLAS,...
Alignment Healthcare Announces Pricing of Secondary Offering
ORANGE, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) (“Alignment Healthcare” or the “Company”), a tech-enabled...
Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit
VANCOUVER and MINNEAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today...
Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering
HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene...
Entourage Health Appoints Seasoned Executive James Afara to Chief Operating Officer
New role optimizes resources in cultivation, production and supply chain for maximum outputTORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Entourage...
Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022
Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentationCAMBRIDGE, Mass., Sept. 16, 2022...
Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China
LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for early intervention to maintain the health of retinal tissue in...
Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union
Standard marketing authorization recommendation applies to all indications and formulations in the European Union, including COMIRNATY® Original/Omicron BA.4-5 and COMIRNATY®...
Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting
Compendium of clinical presentations includes studies with up to 3.5 years of patient follow-up and over 400 eyes treated in...
ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder
At the 10th European Conference on Mental Health (ECMH)Company expects to perform an interim analysis in 1Q23MADRID, Spain and BOSTON,...
CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly
CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly Positive opinion based on MPOWERED Phase 3 trial DUBLIN,...